Abstract
Alzheimer disease (AD) is the most common form of dementia and neurodegenerative disease. Less than 1 % of AD is due to autosomal dominant genes: PSEN 1, PSEN 2, and APP. Susceptibility genes such as APOE contribute to risk in a far larger number of cases. Predictive testing is available for the autosomal dominant genes, but is not recommended for risk genes as they are neither necessary nor sufficient to cause AD. Genetic testing is complicated by capacity to consent, lack of treatment, the need to test an affected family member before predictive testing, and family disagreements about testing.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Alzheimer’s Association. (2013). 2013 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 9(2), 208–245.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4, text rev.th ed.). Washington, DC: American Psychiatric Association.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 34(7), 939–944.
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Jr., Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 7(3), 263–269.
Balasa, M., Gelpi, E., Antonell, A., Rey, M. J., Sánchez-Valle, R., Molinuevo, J. L., et al. (2011). Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology, 76(20), 720–725.
Roberson, E. D., Hesse, J. H., Rose, K. D., Slama, H., Johnson, J. K., Yaffe, K., et al. (2005). Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology, 65(5), 719–725.
Devanand, D. P., Mikhno, A., Pelton, G. H., Cuasay, K., Pradhaban, G., Dileep Kumar, J. S., et al. (2010). Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. Journal of Geriatric Psychiatry and Neurology, 23(3), 185–198.
Massoud, F., & Léger, G. C. (2011). Pharmacological treatment of Alzheimer disease. Canadian Journal of Psychiatry, 56(10), 579–588.
Bird, T. D. (1993). Internet. In R. A. Pagon, T. D. Bird, C. R. Dolan, & K. Stephens (Eds.), GeneReviews. Seattle, WA: University of Washington. 1999 Sep 24 [updated 2010 Dec 23].
Alzheimer Disease & Frontotemporal Dementia Mutation Database. http://www.molgen.ua.ac.be/ADMutations/
McNaughton, D., Knight, W., Guerreiro, R., Ryan, N., Lowe, J., Poulter, M., et al. (2012). Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series. Neurobiology of Aging, 33(2), 426.e13–21.
Basun, H., Bogdanovic, N., Ingelsson, M., Almkvist, O., Näslund, J., Axelman, K., et al. (2008). Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Archives of Neurology, 65(4), 499–505.
Wu, L., Rosa-Neto, P., Hsiung, G. Y., Sadovnick, A. D., Masellis, M., Black, S. E., et al. (2012). Early-onset familial Alzheimer’s disease (EOFAD). Canadian Journal of Neurological Sciences, 39(4), 436–445.
Tanzi R. E. (2012). The genetics of Alzheimer disease. Cold Spring Harbor Perspectives Medicine, 2(10), doi 2:a006296.
Jayadev, S., Leverenz, J. B., Steinbart, E., Stahl, J., Klunk, W., Yu, C. E., et al. (2010). Alzheimer’s disease phenotypes and genotypes associated with mutations in presenilin 2. Brain, 133(Pt 4), 1143–1154.
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., et al. (2006). Role of genes and environments for explaining Alzheimer disease. Archives of General Psychiatry, 63(2), 168–174.
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R., et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA, 278(16), 1349–1356.
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., et al. (2011). APOE and Alzheimer disease: A major gene with semi-dominant inheritance. Molecular Psychiatry, 16(9), 903–907.
Goldman, J. S., Hahn, S. E., Catania, J. W., LaRusse-Eckert, S., Butson, M. B., Rumbaugh, M., et al. (2011). Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genetics in Medicine, 13(6), 597–605. Erratum in: Genet Med, 2011. 13(8), 749.
Ashida, S., Koehly, L. M., Roberts, J. S., Chen, C. A., Hiraki, S., & Green, R. C. (2010). The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: The REVEAL Study. European Journal of Human Genetics, 18(12), 1296–1301.
Vernarelli, J. A., Roberts, J. S., Hiraki, S., Chen, C. A., Cupples, L. A., & Green, R. C. (2010). Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. American Journal of Clinical Nutrition, 91(5), 1402–1407.
Zick, C. D., Mathews, C. J., Roberts, J. S., Cook-Deegan, R., Pokorski, R. J., & Green, R. C. (2005). Genetic testing for Alzheimer’s disease and its impact on insurance purchasing behavior. Health Affairs (Millwood), 24(2), 483–490.
Naj, A. C., Jun, G., Beecham, G. W., Wang, L. S., Vardarajan, B. N., Buros, J., et al. (2011). Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nature Genetics, 43(5), 436–441.
Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J. C., Carrasquillo, M. M., et al. (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nature Genetics, 43(5), 429–435.
Seshadri, S., Fitzpatrick, A. L., Ikram, M. A., DeStefano, A. L., Gudnason, V., Boada, M., et al. (2010). Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA, 303(18), 1832–1840.
Reitz, C., Jun, G., Naj, A., Rajbhandary, R., Vardarajan, B. N., Wang, L. S., et al. (2013). Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4, and the risk of late-onset Alzheimer disease in African Americans. JAMA, 309(14), 1483–1492.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
1 Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Early onset familial Alzheimer disease (MOV 324698 kb)
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Goldman, J.S. (2015). Alzheimer Disease. In: Goldman, J. (eds) Genetic Counseling for Adult Neurogenetic Disease. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7482-2_7
Download citation
DOI: https://doi.org/10.1007/978-1-4899-7482-2_7
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-7481-5
Online ISBN: 978-1-4899-7482-2
eBook Packages: Behavioral ScienceBehavioral Science and Psychology (R0)